VRTX241025C400000
- 83.93
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $490 to $600
Optimistic Buy Rating for Vertex Pharmaceuticals Amid Promising VX-548 Developments
HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 44% Discount?
Vertex Pharmaceuticals' Suzetrigine: A Promising Non-Opioid Solution to Acute Pain Management
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Korro Bio (KRRO) and Vertex Pharmaceuticals (VRTX)
Analysts Are Neutral on These Healthcare Stocks: CVS Health (CVS), Vertex Pharmaceuticals (VRTX)
Cautious Hold on Vertex Pharmaceuticals Amidst Limited New Insights and Awaited Data
Vertex Pharmaceuticals: Strategic Growth and Promising Drug Development Drive Buy Rating
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Bull of the Day: Vertex (VERX)
Market Whales and Their Recent Bets on VRTX Options
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 42% Undervalued
What You Need to Know Ahead of Vertex Pharmaceuticals' Earnings Release
Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
Vertex Coverage Resumed by UBS at Buy on Growth Potential